Search

The use of LAN‐based clusters of computers for computational purposes has been in use for several years with significant success and acceptability. The introduction of the Internet infrastructure as the interconnection medium of the cluster allows for additional flexibility and transparency of such systems. PLEIADES is an Internet‐based parallel/distributed system whose purpose is to allow users to use distant computational resources in order to form virtual clusters. In addition, PLEIADES can be used as a computational infrastructure service provider for applications in need of computational resources. PLEIADES uses a tiered architecture with particular emphasis on the existence of a middle tier, whose task is to assist in the communication between the interface and the resource management tiers. The existence of the middle tier allows for the creation of an open system that is able to easily integrate with new resource management platforms and tools. Since the use of a mature resource management system for parallel/distributed computing was a prerequisite of the PLEIADES architecture, the Condor resource management environment was used. The design and implementation characteristics of PLEIADES together with some experimental uses of the system are also presented. Copyright © 2002 John Wiley & Sons, Ltd.

The purpose of this study was to determine whether ondansentron given to patients with non-small-cell lung cancer (NSCLC) undergoing cisplatin-based chemotherapy, has better antiemetic activity administered every 6 or 8 h in controlling cisplatin-induced emesis. All patients had previously received 3 cycles of cisplatin-based chemotherapy at a dose of 100 mg/m2. Ondansentron was given according to two schedules in group A (50 patients) at a dose of 8 mg in 100 ml normal saline over 10 min i.v. infusion, together with dexamethasone 8 mg before the infusion of cisplatin, continued with both drugs at the same dose and administration after 8 and 16 h; in group B (50 patients) both drugs were administered before the infusion of cisplatin, continued after 6, 12 and 18 h. During the next 3 days, patients continued with tablets of dexamethasone 4 mg and ondansentron 8 mg, group A every 8 h, and group B every 6 h. The only difference in terms of antiemetic response that was noticed between the two groups was the number of patients experiencing nausea which was found increased in group A (n = 32) in comparison to group B (n = 25) (p < 0.022). No difference was noticed in the number of vomiting episodes and retches or emesis control, during the 3-day evaluation period after cisplatin infusion or in side effects. In conclusion, the total dose of 24 mg ondansentron during the acute phase of emesis is as effective as the total dose of 32 mg.